Latest Biologic Stories
ReportsandReports.com adds latest reports on Adalimumab Industry for Global and China Markets to its store. DALLAS, Dec.
First Presentation of Phase 3 Data From Brodalumab Psoriasis Program THOUSAND OAKS, Calif. and LONDON, Dec.
The company leverages its keen understanding of protein purification to achieve the highest purification standards and product quality LONDON, Dec.
NEW YORK, Dec.
Symphogen has licensed the rights to the Selexis SUREtechnology Platform™ and SURE CHO-M Cell Line™ for the development of recombinant monoclonal antibody (MAb) mixtures for the treatment
EDISON, N.J., Dec.
DELHI, India, December 9, 2014 /PRNewswire/ -- Access to this therapy will impact 12 million people suffering from auto immune disorders like rheumatoid arthritis,
- A young chicken: also used as a pet name for children.